| Drug General Information |
| Drug ID |
D00KZF
|
| Former ID |
DNC003753
|
| Drug Name |
BMY-7378
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Terminated |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H31N3O3
|
| InChI |
InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3
|
| InChIKey |
AYYCFGDXLUPJAQ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
5510237, 7978802, 8151616, 11110816, 11113851, 14878226, 26752024, 29221583, 47440473, 50070413, 50071054, 50104690, 53790375, 57321308, 74517605, 85208977, 85788125, 90341693, 103175652, 103808191, 103936501, 104300530, 117592230, 124749543, 124879359, 124879360, 124879361, 124879362, 127479091, 134340958, 135069971, 135650009, 136368030, 137006976, 137952632, 144115742, 162814196, 179150156, 198949361, 223621325, 231780292, 250078613
|
| Target and Pathway |
| Target(s) |
Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[4]
|
| Alpha-1B adrenergic receptor |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04020:Calcium signaling pathway
|
|
AMPK signaling pathway
|
|
Salivary secretionhsa04024:cAMP signaling pathway
|
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
|
Salivary secretion
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Pathway Interaction Database
|
LPA receptor mediated events
|
|
Reactome
|
Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (12/13) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors
|
|
G alpha (12/13) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Endothelin Pathways
|
|
AMPK SignalingWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Vitamin D Receptor Pathway
|
|
AMPK Signaling
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 9). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001317) |
|---|
| REF 3 | J Med Chem. 2005 Apr 21;48(8):3076-9.Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective alpha(1d)-adrenergic receptor antagonists. |
|---|
| REF 4 | J Med Chem. 1996 Mar 1;39(5):1125-9.8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone. |
|---|
